#USA #New York #Class Action #Faruqi & Faruqi #Capricor

Faruqi & Faruqi Invites Capricor Investors to Act

Faruqi & Faruqi, LLP has recently made a call for action directed at investors who have suffered significant losses—exceeding $50,000—due to investments in Capricor Therapeutics, Inc. (NASDAQ: CAPR). The national securities law firm is currently investigating potential claims against Capricor relating to a pending federal securities class action lawsuit. Interested investors are reminded that the deadline to seek the position of lead plaintiff in this case is approaching quickly, set for September 15, 2025.

The lead plaintiff role is pivotal; it involves overseeing the litigation on behalf of the entire class of investors who may have been affected by Capricor's alleged misconduct. This lawsuit specifically addresses claims that Capricor and its executives misled investors regarding the viability of its lead drug, deramiocel, intended for treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD). Claims include the assertion that the company made false and/or misleading statements about their prospects of receiving a Biologics License Application (BLA) approval from the U.S. Food and Drug Administration (FDA).

Background on the Allegations

The firm's complaint alleges that Capricor not only provided investors with overly optimistic projections concerning its BLA status but simultaneously concealed critical adverse information. This information pertained to the results of a Phase 2 HOPE-2 trial that assessed deramiocel's safety and efficacy over four years. Moreover, on July 11, 2025, Capricor shocked the market by revealing that the FDA issued a Complete Response Letter (CRL) rejecting their BLA, citing insufficient evidence for effectiveness and the necessity for further clinical data.

As a result of this announcement, Capricor’s stock price plummeted from $11.40 per share to just $7.64 within a day, a devastating loss for its investors. Faruqi & Faruqi, noted for its robust track record with investors—having recovered hundreds of millions of dollars since its inception in 1995—continues to advocate for individuals potentially impacted by this situation.

What Should Investors Do?

If you are an investor who has incurred losses from Capricor between October 9, 2024, and July 10, 2025, you are encouraged to reach out to the firm to evaluate your legal options. Interested individuals can contact Faruqi & Faruqi partner Josh Wilson directly at either 877-247-4292 or 212-983-9330 (Ext. 1310). The firm also invites any individuals with additional information regarding Capricor’s actions—including whistleblowers and former employees—to come forward.

For those looking to step into a role as lead plaintiff, you can either work through your own legal counsel or choose not to participate. It's important to understand that your right to a potential recovery will remain unchanged regardless of your decision regarding the lead plaintiff role. To learn more about eligibility to join the Capricor class action or to access more resources, visit Faruqi's dedicated page.

Conclusion

As the September 15 deadline looms, Faruqi & Faruqi remains dedicated to ensuring that investors are adequately informed and represented. This case serves as a pivotal moment for those who have been adversely affected by Capricor’s actions. Stay vigilant and proactive in seeking legal counsel to safeguard your investments.